Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Macrocure's CureXcell Phase III Leg Ulcer Study Futile

This article was originally published in Scrip

Executive Summary

Israeli stem cell company Macrocure's lead wound-healing product CureXcell has stumbled in a US Phase III study in venous leg ulcers (VLU) – with a futility analysis revealing that it is not expected to meet its primary endpoint. Shares in the firm dropped by 72% to £3.33 in early trading on Nasdaq on Aug. 20, from a previous day's close of $12.05.

You may also be interested in...



Deal Watch: Amgen BiTEs Back Micromet-Developed Boehringer Antibody

Cancer immunotherapy biotech Leap, backed by HealthCare Ventures and Lilly, reverse-merges with Israel's Macrocure. Elite and SunGen will partner to develop generic versions of four drugs that posted $3bn in aggregate sales over a recent 12-month stretch.

New Era For Schizophrenia Therapy Beckons As Karuna Soars On Promising Phase III Data

The PureTech Health-founded entity believes it has made a significant step forward in the treatment of schizophrenia with its muscarinic-receptor acting agent KarXT, which could offer a completely new way to address all three symptom domains of the disease.

AZ’s Susan Galbraith On What’s Next In The Cancer Pipeline

One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to In Vivo about what’s coming next from the UK major’s cancer pipeline.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC029556

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel